0.00Open0.00Pre Close0 Volume0 Open Interest50.00Strike Price0.00Turnover572.21%IV-35.98%PremiumNov 29, 2024Expiry Date28.10Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9749Delta0.0031Gamma2.76Leverage Ratio-0.7995Theta0.0009Rho2.69Eff Leverage0.0019Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet